|
US5703058A
(en)
*
|
1995-01-27 |
1997-12-30 |
Emory University |
Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
|
|
DE69933860T2
(de)
*
|
1998-02-25 |
2007-05-31 |
Emory University |
2'-fluoronukleoside
|
|
PL364995A1
(en)
|
2000-02-18 |
2004-12-27 |
Shire Biochem Inc. |
Method for the treatment or prevention of flavivirus
|
|
ES2319732T3
(es)
|
2000-04-13 |
2009-05-12 |
Pharmasset, Inc. |
Derivados de nucleosido 3'- o 2'-hidroximetilo sustituido para el tratamiento de infecciones virales.
|
|
MY164523A
(en)
*
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
|
KR20080021797A
(ko)
|
2000-05-26 |
2008-03-07 |
이데닉스(케이만)리미티드 |
플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
|
|
FR2810319A1
(fr)
*
|
2000-06-15 |
2001-12-21 |
Ppg Sipsy |
Composes alpha-phenylsulfinyl-alpha-halogeno-butyrolactone et halogeno-2-buten-2-olide-4 utiles pour la preparation de composes halogeno-2-oxymethyl-4-furanone (4h)
|
|
US20030008841A1
(en)
*
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
|
PT2251015E
(pt)
*
|
2000-10-18 |
2013-04-15 |
Gilead Pharmasset Llc |
Nucleosídeos modificados para o tratamento de infeções virais e de proliferação celular anormal
|
|
BR0206614A
(pt)
*
|
2001-01-22 |
2004-02-17 |
Merck & Co Inc |
Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
|
|
US7105499B2
(en)
*
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
|
US8481712B2
(en)
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
|
WO2002062123A2
(en)
*
|
2001-02-06 |
2002-08-15 |
Yale University |
Novel compounds and methods for inhibiting/treating hiv infections and aids related symptoms
|
|
AU2002255654B2
(en)
|
2001-03-01 |
2008-05-15 |
Pharmasset, Inc. |
Method for the synthesis of 2',3'-dideoxy -2',3'-didehydronucleosides
|
|
AU2002252183A1
(en)
*
|
2001-03-06 |
2002-09-19 |
Biocryst Pharmaceuticals, Inc. |
Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
|
|
GB0112617D0
(en)
|
2001-05-23 |
2001-07-18 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
|
GB0114286D0
(en)
*
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
|
BR0210594A
(pt)
|
2001-06-22 |
2005-11-01 |
Pharmasset Ltd |
(beta)-d ou (beta)-l-3-halonucleosìdeo
|
|
WO2003026589A2
(en)
*
|
2001-09-28 |
2003-04-03 |
Idenix (Cayman) Limited |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
|
US7049303B2
(en)
|
2001-11-07 |
2006-05-23 |
Medical Research Council |
Inhibition of viruses
|
|
CN100560073C
(zh)
*
|
2001-12-14 |
2009-11-18 |
法玛塞特公司 |
用于治疗病毒感染的n4-酰基胞嘧啶核苷
|
|
WO2003068162A2
(en)
*
|
2002-02-14 |
2003-08-21 |
Pharmasset Ltd. |
Modified fluorinated nucleoside analogues
|
|
JP2005533824A
(ja)
*
|
2002-06-28 |
2005-11-10 |
イデニクス（ケイマン）リミテツド |
フラビウイルス科感染の治療のための２’−ｃ−メチル−３’−ｏ−ｌ−バリンエステルリボフラノシルシチジン
|
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
|
JP2005533817A
(ja)
*
|
2002-06-28 |
2005-11-10 |
イデニクス（ケイマン）リミテツド |
フラビウィルス科ウィルス感染治療用の修飾２′および３′−ヌクレオシドプロドラッグ
|
|
NZ537662A
(en)
*
|
2002-06-28 |
2007-10-26 |
Idenix Cayman Ltd |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
|
US20040067877A1
(en)
|
2002-08-01 |
2004-04-08 |
Schinazi Raymond F. |
2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
|
|
KR20050040912A
(ko)
|
2002-08-01 |
2005-05-03 |
파마셋 인코포레이티드 |
플라비비리다에 감염 치료용의 비사이클로[4.2.1]노난시스템을 가지는 화합물
|
|
US6884880B2
(en)
*
|
2002-08-21 |
2005-04-26 |
Ash Stevens, Inc. |
Process for the preparation of 9-β-anomeric nucleoside analogs
|
|
US7902203B2
(en)
*
|
2002-11-01 |
2011-03-08 |
Abbott Laboratories, Inc. |
Anti-infective agents
|
|
US7824851B2
(en)
*
|
2002-11-15 |
2010-11-02 |
Idenix Pharmaceuticals, Inc. |
2′-branched nucleosides and Flaviviridae mutation
|
|
EP1585529A4
(en)
*
|
2002-12-12 |
2008-05-28 |
Idenix Cayman Ltd |
PROCESS FOR PREPARING 2'-BRANCHED NUCLEOSIDES
|
|
WO2004058792A1
(en)
*
|
2002-12-23 |
2004-07-15 |
Idenix (Cayman) Limited |
Process for the production of 3'-nucleoside prodrugs
|
|
AU2004224575A1
(en)
*
|
2003-03-28 |
2004-10-07 |
Pharmasset Ltd. |
Compounds for the treatment of flaviviridae infections
|
|
WO2004096149A2
(en)
*
|
2003-04-28 |
2004-11-11 |
Idenix (Cayman) Limited |
Industrially scalable nucleoside synthesis
|
|
ES2586668T5
(es)
*
|
2003-05-30 |
2024-11-12 |
Gilead Pharmasset Llc |
Análogos de nucleósidos fluorados modificados
|
|
KR20060035652A
(ko)
|
2003-06-30 |
2006-04-26 |
이데닉스 (케이만) 리미티드 |
β-Ｌ-2-데옥시 뉴클레오시드의 합성
|
|
RU2006105640A
(ru)
*
|
2003-07-25 |
2007-09-10 |
Айденикс (Кайман) Лимитед (Ky) |
Аналоги пуриновых нуклеозидов для лечения flaviviridae, включая гепатит с
|
|
WO2005018330A1
(en)
*
|
2003-08-18 |
2005-03-03 |
Pharmasset, Inc. |
Dosing regimen for flaviviridae therapy
|
|
WO2005021568A2
(en)
|
2003-08-27 |
2005-03-10 |
Biota, Inc. |
Novel tricyclic nucleosides or nucleotides as therapeutic agents
|
|
WO2005026186A1
(de)
*
|
2003-09-12 |
2005-03-24 |
Max-Delbrück-Centrum für Molekulare Medizin |
Β-l-nucleoside und ihre verwendung als pharmazeutische mittel zur behandlung viraler erkrankungen
|
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
|
US20050182252A1
(en)
|
2004-02-13 |
2005-08-18 |
Reddy K. R. |
Novel 2'-C-methyl nucleoside derivatives
|
|
KR100839394B1
(ko)
*
|
2004-06-09 |
2008-06-20 |
에프. 호프만-라 로슈 아게 |
피라졸로 피리미딘
|
|
US7405220B2
(en)
*
|
2004-06-09 |
2008-07-29 |
Hoffmann-La Roche Inc. |
Pyrazolopyrimidines
|
|
EP1758453B1
(en)
|
2004-06-15 |
2014-07-16 |
Merck Sharp & Dohme Corp. |
C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
|
|
JP2008503562A
(ja)
*
|
2004-06-23 |
2008-02-07 |
イデニクス（ケイマン）リミテツド |
フラビウイルス科による感染症を治療するための５−アザ−７−デアザプリン誘導体
|
|
EP1773355B1
(en)
|
2004-06-24 |
2014-06-25 |
Merck Sharp & Dohme Corp. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
|
CA2577526A1
(en)
*
|
2004-08-23 |
2006-03-02 |
Joseph Armstrong Martin |
Antiviral 4'-azido-nucleosides
|
|
WO2006031725A2
(en)
|
2004-09-14 |
2006-03-23 |
Pharmasset, Inc. |
Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
|
WO2006093801A1
(en)
*
|
2005-02-25 |
2006-09-08 |
Abbott Laboratories |
Thiadiazine derivatives useful as anti-infective agents
|
|
US7524831B2
(en)
|
2005-03-02 |
2009-04-28 |
Schering Corporation |
Treatments for Flaviviridae virus infection
|
|
WO2006094347A1
(en)
|
2005-03-08 |
2006-09-14 |
Biota Scientific Management Pty Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
|
JP4516863B2
(ja)
*
|
2005-03-11 |
2010-08-04 |
株式会社ケンウッド |
音声合成装置、音声合成方法及びプログラム
|
|
CA2606195C
(en)
|
2005-05-02 |
2015-03-31 |
Merck And Co., Inc. |
Hcv ns3 protease inhibitors
|
|
US7470664B2
(en)
|
2005-07-20 |
2008-12-30 |
Merck & Co., Inc. |
HCV NS3 protease inhibitors
|
|
US8278322B2
(en)
|
2005-08-01 |
2012-10-02 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
|
US7705009B2
(en)
*
|
2005-11-22 |
2010-04-27 |
Hoffman-La Roche Inc. |
4-aminopyrimidine-5-thione derivatives
|
|
EP1957510A1
(en)
|
2005-12-09 |
2008-08-20 |
F.Hoffmann-La Roche Ag |
Antiviral nucleosides
|
|
EP1971611B1
(en)
|
2005-12-21 |
2012-10-10 |
Abbott Laboratories |
Anti-viral compounds
|
|
JP2009521479A
(ja)
*
|
2005-12-21 |
2009-06-04 |
アボット・ラボラトリーズ |
抗ウイルス化合物
|
|
CN102702194A
(zh)
|
2005-12-21 |
2012-10-03 |
雅培制药有限公司 |
抗病毒化合物
|
|
EP2345652A1
(en)
|
2005-12-21 |
2011-07-20 |
Abbott Laboratories |
Antiviral compounds
|
|
CA2634749C
(en)
*
|
2005-12-23 |
2014-08-19 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
|
KR101237312B1
(ko)
*
|
2006-02-10 |
2013-03-04 |
삼진제약주식회사 |
피리미딘다이온 유도체를 포함하는 ｃ형 간염의 예방 및치료용 약학 조성물
|
|
US8895531B2
(en)
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
|
WO2010005847A1
(en)
*
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Acid-degradable and bioerodible modified polyhydroxylated materials
|
|
US9644039B2
(en)
*
|
2006-03-24 |
2017-05-09 |
The Regents Of The University Of California |
Acid-degradable and bioerodible modified polyhydroxylated materials
|
|
KR101059593B1
(ko)
|
2006-04-11 |
2011-08-25 |
노파르티스 아게 |
Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
|
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
US7662958B2
(en)
*
|
2006-07-19 |
2010-02-16 |
Rolf Wagner |
Anti-infective agents
|
|
US20090298708A1
(en)
*
|
2006-08-23 |
2009-12-03 |
Masad Damha J |
2'-deoxy-2'-fluoro-beta-d-arabinonucleoside 5'-triphosphates and their use in enzymatic nucleic acid synthesis
|
|
ES2429290T3
(es)
*
|
2006-10-10 |
2013-11-14 |
Gilead Pharmasset Llc |
Preparación de nucleósidos de ribofuranosilpirimidinas
|
|
AU2007306405A1
(en)
*
|
2006-10-10 |
2008-04-17 |
Medivir Ab |
HCV nucleoside inhibitor
|
|
EP2079480B1
(en)
|
2006-10-24 |
2013-06-05 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
EP2076278B1
(en)
|
2006-10-24 |
2015-05-06 |
Merck Sharp & Dohme Corp. |
Macrocyclic HCV NS3 protease inhibitors
|
|
WO2008051475A2
(en)
|
2006-10-24 |
2008-05-02 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
|
EP2083844B1
(en)
|
2006-10-27 |
2013-11-27 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
BRPI0718161A2
(pt)
|
2006-10-27 |
2013-11-26 |
Merck & Co Inc |
Composto, composição farmacêutica, e, uso do composto.
|
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
WO2008133753A2
(en)
*
|
2006-12-20 |
2008-11-06 |
Abbott Laboratories |
Anti-viral compounds
|
|
EP2121707B1
(en)
|
2006-12-20 |
2012-12-05 |
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. |
Antiviral indoles
|
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
US8071568B2
(en)
|
2007-01-05 |
2011-12-06 |
Merck Sharp & Dohme Corp. |
Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
|
|
DK2144604T3
(da)
|
2007-02-28 |
2011-10-17 |
Conatus Pharmaceuticals Inc |
Fremgangsmåder til behandling af kronisk viral hepatitis C under anvendelse af RO 113-0830
|
|
JP5417184B2
(ja)
*
|
2007-03-23 |
2014-02-12 |
サザン リサーチ インスティテュート |
関節炎を治療及び予防する方法
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
CN100532388C
(zh)
|
2007-07-16 |
2009-08-26 |
郑州大学 |
2’-氟-4’-取代-核苷类似物、其制备方法及应用
|
|
CN101754970B
(zh)
|
2007-07-17 |
2013-07-10 |
P.安杰莱蒂分子生物学研究所 |
用于治疗丙型肝炎的大环吲哚衍生物
|
|
US8927569B2
(en)
|
2007-07-19 |
2015-01-06 |
Merck Sharp & Dohme Corp. |
Macrocyclic compounds as antiviral agents
|
|
WO2009058800A2
(en)
*
|
2007-10-29 |
2009-05-07 |
President And Fellows Of Harvard College |
Synthesis of nucleosides
|
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
|
EP2271345B1
(en)
|
2008-04-28 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
US20090274686A1
(en)
*
|
2008-05-02 |
2009-11-05 |
Yat Sun Or |
Nucleoside phosphonate derivatives
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
CN102177172A
(zh)
|
2008-07-02 |
2011-09-07 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
|
WO2010002877A2
(en)
|
2008-07-03 |
2010-01-07 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
|
ME02132B
(me)
|
2008-07-22 |
2014-08-22 |
Merck Sharp & Dohme |
Kombinacije makrocikličnog jedinjenja hinoksalina koje je inhibitor hcv ns3 proteaze sa drugim hcv sredstvima
|
|
EA019341B1
(ru)
|
2008-12-23 |
2014-02-28 |
Джилид Фармассет, Ллс. |
Фосфорамидаты нуклеозидов
|
|
EP2376514A2
(en)
|
2008-12-23 |
2011-10-19 |
Pharmasset, Inc. |
Nucleoside analogs
|
|
BRPI0923815A2
(pt)
*
|
2008-12-23 |
2015-07-14 |
Pharmasset Inc |
Síntese de nucleosídeos de purina
|
|
WO2010082050A1
(en)
|
2009-01-16 |
2010-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
|
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス，インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
|
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
|
AU2010249119A1
(en)
*
|
2009-05-12 |
2011-12-01 |
Southern Research Institute |
2'-fluoro arabino nucleosides and use thereof
|
|
MX2011012155A
(es)
|
2009-05-13 |
2012-02-28 |
Enanta Pharm Inc |
Compuestos macrociclicos como inhibidores del virus de hepatitis c.
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
WO2011014487A1
(en)
|
2009-07-30 |
2011-02-03 |
Merck Sharp & Dohme Corp. |
Hepatitis c virus ns3 protease inhibitors
|
|
WO2011014882A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
|
|
CA2769652A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
|
JP2013511030A
(ja)
|
2009-11-14 |
2013-03-28 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｈｃｖ治療の迅速な反応を予測するためのバイオマーカー
|
|
US8816074B2
(en)
*
|
2009-11-16 |
2014-08-26 |
University of Georgia Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
|
US9700560B2
(en)
|
2009-11-16 |
2017-07-11 |
University Of Georgia Research Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
|
WO2011063076A1
(en)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Methods of treating hepatitis c virus with oxoacetamide compounds
|
|
BR112012011393A2
(pt)
|
2009-12-02 |
2017-06-20 |
Hoffmann La Roche |
biomarcadores para a previsão da resposta sustentada ao tratamento de hcv
|
|
NZ600608A
(en)
|
2009-12-18 |
2015-01-30 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
|
LT2609923T
(lt)
|
2010-03-31 |
2017-09-11 |
Gilead Pharmasset Llc |
(s)-izopropilo 2-(((s)-(perfluorfenoksi)(fenoksi)fosforil)amino)-propanoato kristalinimo būdas
|
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
|
AR094621A1
(es)
|
2010-04-01 |
2015-08-19 |
Idenix Pharmaceuticals Inc |
Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
|
|
US9284188B2
(en)
|
2010-09-03 |
2016-03-15 |
The Regents Of The University Of California |
Cytosolic delivery of materials with endosome-disrupting colloids
|
|
EA029145B1
(ru)
|
2010-09-21 |
2018-02-28 |
Энанта Фармасьютикалз, Инк. |
Ингибиторы hcv сериновой протеазы, полученные из макроциклического пролина
|
|
US9011833B2
(en)
|
2010-10-08 |
2015-04-21 |
Novartis Ag |
Vitamin E formulations of sulfamide NS3 inhibitors
|
|
US8841275B2
(en)
|
2010-11-30 |
2014-09-23 |
Gilead Pharmasset Llc |
2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
TW201309690A
(zh)
|
2011-02-10 |
2013-03-01 |
Idenix Pharmaceuticals Inc |
巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
|
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
US9150603B2
(en)
|
2011-04-13 |
2015-10-06 |
Merck Sharp & Dohme Corp. |
2′-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
|
|
EP2697242B1
(en)
|
2011-04-13 |
2018-10-03 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
PE20140522A1
(es)
|
2011-04-13 |
2014-05-03 |
Merck Sharp & Dohme |
Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
|
|
EP2731434A4
(en)
|
2011-07-13 |
2014-12-31 |
Merck Sharp & Dohme |
5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
|
|
WO2013009737A1
(en)
|
2011-07-13 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
|
|
EP2755983B1
(en)
|
2011-09-12 |
2017-03-15 |
Idenix Pharmaceuticals LLC. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
|
WO2013039855A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
CA2840242C
(en)
|
2011-09-16 |
2019-03-26 |
Gilead Sciences, Inc. |
Methods for treating hcv
|
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
|
EP2776438A4
(en)
*
|
2011-11-10 |
2015-04-29 |
Inhibitex Inc |
SUBSTITUTED PURIN NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR THE TREATMENT OF VIRUS INFECTIONS
|
|
WO2013074386A2
(en)
|
2011-11-15 |
2013-05-23 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
US9089574B2
(en)
|
2011-11-30 |
2015-07-28 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
|
US20140356325A1
(en)
|
2012-01-12 |
2014-12-04 |
Ligand Pharmaceuticals Incorporated |
Novel 2'-c-methyl nucleoside derivative compounds
|
|
US20130217644A1
(en)
|
2012-02-13 |
2013-08-22 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
|
|
JP2015517975A
(ja)
|
2012-02-14 |
2015-06-25 |
ユニバーシティ オブ ジョージア リサーチ ファウンデーション インコーポレイテッド |
フラビウイルス感染の処置のためのスピロ［２．４］ヘプタン
|
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
|
JP6165848B2
(ja)
|
2012-05-22 |
2017-07-19 |
イデニク ファーマシューティカルズ エルエルシー |
肝疾患のためのｄ−アミノ酸化合物
|
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
EA027929B1
(ru)
|
2012-05-25 |
2017-09-29 |
Янссен Сайенсиз Айрлэнд Юси |
Нуклеозиды на основе урацила и спирооксетана
|
|
US9192621B2
(en)
|
2012-09-27 |
2015-11-24 |
Idenix Pharmaceuticals Llc |
Esters and malonates of SATE prodrugs
|
|
JP2015532277A
(ja)
|
2012-09-29 |
2015-11-09 |
ノバルティス アーゲー |
環状ペプチドおよび医薬としてのその使用
|
|
HK1207647A1
(en)
|
2012-10-08 |
2016-02-05 |
Idenix Pharmaceuticals Llc |
2'-chloro nucleoside analogs for hcv infection
|
|
EP2909223B1
(en)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Dinucleotide compounds for hcv infection
|
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
|
WO2014078427A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
EA201590943A1
(ru)
|
2012-12-21 |
2016-01-29 |
Алиос Биофарма, Инк. |
Замещенные нуклеозиды, нуклеотиды и их аналоги
|
|
EP3650013A1
(en)
|
2013-01-31 |
2020-05-13 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
|
WO2014121417A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014121418A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
|
WO2014160484A1
(en)
|
2013-03-13 |
2014-10-02 |
Idenix Pharmaceuticals, Inc. |
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
|
|
RU2534613C2
(ru)
|
2013-03-22 |
2014-11-27 |
Александр Васильевич Иващенко |
Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
|
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
|
EP3027636B1
(en)
|
2013-08-01 |
2022-01-05 |
Idenix Pharmaceuticals LLC |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
|
SI3038601T1
(sl)
|
2013-08-27 |
2020-07-31 |
Gilead Pharmasset Llc |
Formulacija kombinacije dveh protivirusnih spojin
|
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
|
US10351918B2
(en)
|
2013-10-30 |
2019-07-16 |
Green Life Biotech, Llc |
Pathogenesis quantification systems and treatment methods for citrus greening blight
|
|
EP3063165A1
(en)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
|
EP3074399A1
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
|
EP3083654A1
(en)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or nucleosides for the treatment of hcv
|
|
CA2937548C
(en)
|
2014-02-13 |
2022-10-25 |
Ligand Pharmaceuticals, Inc. |
Prodrug compounds and their uses
|
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
WO2016003812A1
(en)
|
2014-07-02 |
2016-01-07 |
Ligand Pharmaceuticals, Inc. |
Prodrug compounds and uses therof
|
|
KR102363946B1
(ko)
|
2015-03-06 |
2022-02-17 |
아테아 파마슈티컬즈, 인크. |
HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
|
|
JP6743135B2
(ja)
*
|
2015-09-02 |
2020-08-19 |
アッヴィ・インコーポレイテッド |
抗ウィルス性テトラヒドロフラン誘導体
|
|
US10202412B2
(en)
|
2016-07-08 |
2019-02-12 |
Atea Pharmaceuticals, Inc. |
β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
|
|
US10711029B2
(en)
|
2016-07-14 |
2020-07-14 |
Atea Pharmaceuticals, Inc. |
Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
|
|
HRP20220278T1
(hr)
|
2016-09-07 |
2022-05-13 |
Atea Pharmaceuticals, Inc. |
2'-supstituirani-n6-supstituirani purinski nukleotidi za liječenje bolesti izazvanih rnk virusima
|
|
EP3554258B1
(en)
|
2016-12-15 |
2023-07-19 |
Société des Produits Nestlé S.A. |
Compositions and methods that modulate phosphorus or enzymes in a companion animal
|
|
WO2018109666A1
(en)
|
2016-12-15 |
2018-06-21 |
Nestec Sa |
Compositions and methods that modulate cholesterol in a companion animal
|
|
IL295609B2
(en)
|
2017-02-01 |
2023-11-01 |
Atea Pharmaceuticals Inc |
Nucleotide hemisulfate salt for the treatment of hepatitis C virus
|
|
PT3661937T
(pt)
|
2017-08-01 |
2021-09-24 |
Gilead Sciences Inc |
Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
|
|
RU2020126177A
(ru)
|
2018-01-09 |
2022-02-10 |
Лиганд Фармасьютикалз, Инк. |
Ацетальные соединения и их терапевтическое применение
|
|
WO2019200005A1
(en)
|
2018-04-10 |
2019-10-17 |
Atea Pharmaceuticals, Inc. |
Treatment of hcv infected patients with cirrhosis
|
|
JP7496132B2
(ja)
*
|
2018-08-31 |
2024-06-06 |
国立大学法人 鹿児島大学 |
核酸アナログ及び抗ｂ型肝炎ウイルス剤
|
|
KR102835299B1
(ko)
|
2018-12-04 |
2025-07-18 |
브리스톨-마이어스 스큅 컴퍼니 |
다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법
|
|
US10874687B1
(en)
|
2020-02-27 |
2020-12-29 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against COVID-19
|
|
WO2022245814A1
(en)
*
|
2021-05-17 |
2022-11-24 |
Rome Therapeutics, Inc. |
Methods of treating medical conditions and inhibiting line1 reverse transcriptase using a substituted 4-fluoro-2,5-dihydrofuranyl phosphonic acid or related compound
|
|
MX2023014898A
(es)
|
2021-06-17 |
2024-04-29 |
Atea Pharmaceuticals Inc |
Terapia combinada anti-vhc ventajosa.
|